NCT04761107|Active Not RecruitingDMC
Impact of COVID-19 on GU Disease
Mitigating Risk of COVID-19 for Clinical Management of Genitourinary Diseases
Loading search results
Mitigating Risk of COVID-19 for Clinical Management of Genitourinary Diseases
Sponsor study identifier
Secondary identifiers
OTHER · Icahn School of Medicine at Mount Sinai
observational
15,240
1 country
1
Study Start
February 18, 2021
Actual (reported)Primary Completion
February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to:
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 17, 2021
Actual (reported)February 18, 2021
Actual (reported)February 18, 2021
Actual (reported)February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Proportion of patients with a new diagnosis of GU
Proportion of patients with a new diagnosis of GU cancer and with active or past infection with SARS-Co-V-2
Day 1
Proportion of GU cancer patients, with active disease or in remission
Day 1
Proportion of patients with the benign urologic condition
Day 1
GU patients from medical records with active or past infection of SARS-Co-V-2
Patients seen in the Urology Department at Mount Sinai.
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Chakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V, Mohamed N, Lundon D, Dovey Z, Kyprianou N, Tewari AK. Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. Commun Biol. 2020 Jul 8;3(1):374. doi: 10.1038/s42003-020-1088-9.
Lundon DJ, Kelly BD, Nair S, Bolton DM, Kyprianou N, Wiklund P, Tewari A. Early mortality risk stratification after SARS-CoV-2 infection. Med Intensiva (Engl Ed). 2020 Jul 4;45(8):e40-2. doi: 10.1016/j.medin.2020.06.011. Online ahead of print. No abstract available.
1. Peripheral blood - plasma and serum for PBMCs and aliquots. 2. Urine
Ashutosh K Tewari, MD
Icahn School of Medicine at Mount Sinai
Dimple Chakravarty, PhD
Icahn School of Medicine at Mount Sinai
Sujit S Nair, PhD
Icahn School of Medicine at Mount Sinai
15,240 participants (actual enrollment reported by the registry).
First Submitted
February 17, 2021
First Posted
February 18, 2021
Study Start
February 18, 2021
Actual (reported)CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19
Contact the study team to confirm eligibility.
Pavlova IP, Nair SS, Kyprianou N, Tewari AK. The Rapid Coronavirus Antibody Test: Can We Improve Accuracy? Front Med (Lausanne). 2020 Sep 2;7:569. doi: 10.3389/fmed.2020.00569. eCollection 2020. No abstract available.
Theise ND, Arment AR, Chakravarty D, Gregg JMH, Jacobson IM, Jung KH, Nair SS, Tewari AK, Thurston AW, Van Drie J, Westover JB. Clinical stage molecule PT150 is a modulator of glucocorticoid and androgen receptors with antiviral activity against SARS-CoV-2. Cell Cycle. 2020 Dec;19(24):3632-3638. doi: 10.1080/15384101.2020.1859752. Epub 2020 Dec 11.
Primary Completion
February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
February 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
January 31, 2025
Record last verified: 2025-01
All of the individual participant data collected during the trial, after deidentification.
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: